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Introduction
Coronary artery bypass grafting (CABG), via median sternotomy 
is the most common cardiac operation [1]. This operation may 
be associated with several complications and one of the most 
significant is myocardial damage. The usual technique involves 
the institution of cardiopulponary bypass (CPB) and inducing 
cardiac arrest in diastole using potassium rich cardioplegia 
with cross clamping of the aorta and a consequent ischaemic 
period to the heart. The myocardial damage occurring during 
this ischaemic period is attenuated by inducing cardiac arrest in 
diastole and by lowering myocardial temperature [2,3]. Various 
myocardial management strategies exist and each method has 
its advantages and limitations.
This study was performed using one method of myocardial 
protection to assess the effect of several variables on myocardial 
protection. The possible variables that could influence 
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Highlights
Background 
Myocardial cell ischaemic injury during cardiopulmonary bypass and aortic crossclamp remains a key limiting factor to patient 
outcomes in coronary artery bypass grafting. Troponin I has been shown to be an effective indicator of myocardial ischaemic injury 
and achieves peak levels early post-operatively.
Methods 
All consenting CABG patients from one centre, during a one year period, were recruited. All surgeries were performed using identical 
techniques besides the cardioplegia volume and number of doses. Troponin I levels were checked regularly post-operatively until a 
peak troponin I level was ascertained. All the patient demographics, crossclamp times, bypass times and cardioplegia dosing were 
analysed using multiple combinations of statistical tools. 
Results  
172 patients were included in the study and cardiopulmonary bypass (CPB) time was found to be significant as a single variable 
(p=0.033). The combination of CBP time and ischaemia time (p=0.002) and the combination of CPB time and multidose cardioplegia 
(p=0.009), were both found to significantly affect peak troponin I levels. Another analysis was performed on the volume of 
cardioplegia used. While this was not significant as an individual variable it did become significant when combined with ischaemia 
time at a threshold total cardioplegia volume of 750mls (p=0.026). 
Conclusions  
The conclusion therefore is that using over 750mls of cardioplegia in multiple doses will safely protect against an ischaemia time 
of up to 62min. However there is no protection against the CPB time, which proved to have the most impact on myocardial cell 
damage in our practice. 
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myocardial protection were the patient’s demographics, the 
total volume of cardioplegia given and the number of divided 
doses it was given in, the aortic cross clamp (ischaemic) time 
and the CPB time.
An effective and sensitive way of monitoring myocardial cell 
damage is through measurement of early post-operative 
myocardial enzyme release [4,5]. Troponin I was identified as 
the most widely used marker in the literature and was readily 
available in the hospital during this study [6]. Most studies 
indicated that the peak value of post-operative troponin I was 
the most significant indicator of myocardial injury, with levels 
reaching almost 20 times the normal reference [7]. In most cases 
troponin I peaked within 18 hours of surgery and decreased 
steadily thereafter [8].
Methods
All patients undergoing elective CABG over a one-year period 
(January-December 2011) were recruited prospectively. Written 
consent was obtained from all patients and the study was 
endorsed by the local research council. The surgeries were 
performed by the same 5 surgeons using identical techniques. 
Median sternotomy was performed followed by harvest of the 
left internal thoracic artery (LITA) and institution of full aorto-
atrial cardiopulmonary bypass. Cold blood cardioplegia using 
Martindale Pharma® cardioplegia concentrate (20mls diluted with 
180mls of saline) and mixed with 800mls of blood was infused 
antegradely. The LITA was grafted on the left anterior descending 
artery. Long saphenous vein segments were harvested using an 
open technique and were used to bypass the other coronary 
arteries. After the distal anastomoses were completed the cross 
clamp was removed allowing cardiac activity to resume and 
the proximal anastomoses were sutured to punched holes in 
the aorta. The LITA perfused the heart for 2 minutes prior to the 
release of the aortic cross clamp and no special reperfusion was 
used in any of the cases. Patients suffering from a postoperative 
myocardial infarction, diagnosed on clinical, electrocardiographic 
and echo- cardiographic features were excluded from analysis.
Troponin I levels were taken at 2, 6, 12, 24 and 48 hours post-
operatively. Sample collection was stopped if the results showed 
that the troponin levels began to decrease. The highest value was 
taken as the peak troponin level. All data including demographics 
and pre-operative criteria such as logistic Euroscore, haematocrit, 
left main stem lesions, and renal function were recorded. 
Intra-operative values such as cardioplegia volume, timing of 
each of cardioplegia infusion, duration of cardiac ischaemia 
and cardiopulmonary bypass times, presence and nature of 
arrhythmias, intra-operative haematocrit, acid-base status and 
arterial and graft size and quality were documented.  Immediately 
post-operative inotrope requirements and use of intra-aortic 
balloon pumps were documented.
Statistical Analysis
All the data collected was analysed with respect to the peak 
troponin I levels using SPSS v.21 (IBM) by a professional 
statistician. A logarithmic transformation to troponin I values 
was carried out to reduce the data skewness. The normality 
assumption was then checked using the Kolmogorov Smirnov 
test. The individual criteria were compared to the peak troponin 
I levels using the one-way ANOVA test if the variables were 
categorical or a bivariate Pearson two-tailed correlation test if the 
variables were metric. A 0.05 level of significance was adopted 
for all tests. 
The goal of this study is to assess the collective impact of the 
individual criteria on troponin I. This was carried out by fitting a 
General Linear Model (GLM) assuming a Normal distribution and 
an identity link function.  This model related the log-transformed 
troponin I to the individual criteria that were identified to be 
significant or almost significant in univariate analysis.
Results
The sample comprised 174 patients, two of whom were removed 
because of incomplete information, totalling 172 patients (83% 
males and 17% females). The average age was 64.4 years with 
27% of patients being over 70 years. 52% of patients underwent 
a CABG x3, while 34% underwent CABG x2. Only 4.7% and 
8.7% received 1 or 4 grafts respectively.
The peak post-operative troponin I level ranged from 0.7 to 180 
(normal range 0-0.29mg/ml), with a mean of 13.5 and a median 
of 5.9. 13.5% of patients had a troponin above 20, therefore the 
majority where within 0.7 and 20.
The bypass time distribution, ranging from 25 till 116 minutes, 
is marginally right skewed and the average bypass time for 171 
patients was 65 minutes after eliminating one patient due to 
missing data.
The Kolmogorov-Smirnov test was first used to assess the 
normality assumption of the peak troponin I level distribution. 
The null hypothesis specifies that the distribution is normal and 
is accepted if the p-value exceeds the 0.05 level of significance. 
The alternative hypothesis specifies that the distribution is 
skewed  and would be accepted if the p-value is less than the 
0.05 criterion.
It is clear from the histogram and Kolmogorov-Smirnov test that 
the peak troponin I level distribution is considerably right skewed 
and does not satisfy the normality assumption (graph 1).
The same test was used to assess the normality assumption 
of log-transformed  peak troponin distribution distribution. 
The histogram (graph 2) shows that  the Log Peak Troponin I 
distribution is marginally right skewed; however the Kolmogorov 
Smirnov test indicates that the normality assumption is satisfied 
since the p-value (p=0.136) exceeds the 0.05 criterion.
Log Peak Troponin I levels was related to each individual 
criterion using either Pearson correlation, if the criterion had 
a metric scale, or the One-Way ANOVA test if the criterion 
had a categorical scale.  Table 1 displays the p-value of each 
univariate analysis.
The scatter plot (graph 3) displays the linear relationship between 
ischaemia time, bypass time and the Log Peak Troponin.  All 
relationships are positive, which implies that an increase in one 
variable results in an increase in the other two variables. The 
relationship between ischaemia time and bypass time is the 
stronger one, while the relationship between log peak troponin 
and ischaemic time is the weaker one.
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The log-transformed peak troponin I levels was analysed further 
using general linear models with log peak troponin I as the 
dependent variable, and bypass time, ischaemia time, number 
of CP doses and total CP volume as the predictors. The pairwise 
interaction effect between the predictors was also analysed. In 
some of the models the number of CP doses was categorised as 
(no dose, multiple doses) and total CP volume was categorised 
as (below 750, above 750). 
GLMs were also used to assess the impact of any two strong 
predictors and their interaction effect on log peak troponin I 
levels. Significance was noted when analyzing cardiac ischaemia 
time. The significant interactions were with ventricular fibrillation 
(VF) on removing the cross clamp (p=0.017) and with the total 
volume of cardioplegia (CP).
Graph 4 shows the relationship between log peak troponin, 
bypass time and a grouped version of the number of CP doses. 
Tests of between-subject effects show that both main effects 
and their interaction effects are significant since their p-values 
are less than the 0.05 level of significance. Graph 4 displays that 
log peak troponin increases with an increase in bypass time; 
however this increase is more conspicuous for patients taking 
one dose. For patients given one CP dose, the log peak troponin 
is larger in a long bypass durations and smaller in short bypass 
durations, compared to patients given multiple CP doses.
Log peak troponin was examined further by clustering the patients 
in two cardioplegia volume groups; those receiving more than a 
certain CP dose and those receiving less. This threshold CP dose 
was incremented in steps of 50 ml and each time analyzed using 
GLM. Models using threshold CP doses of 700 ml or less yielded 
no significant results; however, models using threshold CP doses 
of 750 ml or more yielded interesting results. Graph 5 displays 
the relationship between log peak troponin, ischaemia time and 
a grouped version of CP volume.  It shows that log peak troponin 
increases with an increase in ischaemia time; however this 
increase is more conspicuous for patients taking less than 750 
ml.  For patients given less than 750 ml CP dose, the log peak 
troponin is larger in a long ischeamia times and smaller in short 
ischeamia times, compared to patients given more than 750 ml 
CP dose. Tests of between-subject effects show that none of the 
effects are significant at the 0.05 level of significance, indicating 
that these relationships may be attributed to chance.
Graph 6 displays the relationship between log peak troponin, CP 
volume and a grouped version of the number of CP doses. It shows 
that log peak troponin increases marginally with an increase in 
total CP volume when one CP dose is provided; however, log 
peak troponin decreases marginally with an increase in total CP 
volume when multiple CP doses are provided. Tests of between-
subject effects show that none of the effects are significant at the 
0.05 level of significance, indicating that these relationships may 
be attributed to chance.
Graph 7 displays the relationship between log peak troponin, 
ischaemia time and a grouped version of the number of CP doses. 
It shows that log peak troponin increases with an increase in 
ischaemia time; however this increase is slightly more conspicuous 
for patients taking one CP dose.  Tests of between-subject effects 
show that none of the effects are significant at the 0.05 level, 
indicating that these relationships may be attributed to chance.
Graph 1. Peak Troponin distribution
Kolmogorov-Smirnov test to assess normality of peak troponin 
distribution
One-Sample Kolmogorov-Smirnov Test
Peak Troponin
 Kolmogorov-Smirnov Z 4.128
 P-value (2-tailed) 0.000
Graph 2. Log-Peak Troponin distribution
Kolmogorov-Smirnov test to assess normality of log-peak 
troponin distribution
One-Sample Kolmogorov-Smirnov Test
Peak Troponin
Kolmogorov-Smirnov Z 1.159
P-value (2-tailed) 0.136
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Discussion
The number of patients included was of adequate size with a 
good demographic and geographical representation. Around a 
quarter of patients were over 70-years-old, logistic Euroscores 
varied from 0.88 to 34.5 (mean: 2.3, median: 1.68) and half were 
below 2. The duration of cardiac ischaemia varied from 11 to 
62 minutes (mean: 34.9 minutes), however ejection fraction 
was predominantly good with only 9% being moderate and no 
cases of poor ventricular function. This therefore means that 
the conclusions drawn from this study may not be applicable 
to cases with very low ejection fractions. The contents of the 
cardioplegia solution was identical throughout all the cases and 
the troponin I tests were analyzed by the same laboratory using 
the Immulite 2000® kits throughout the entire study.
The first set of results came from analyzing one variable 
against peak troponin I levels (table 1). There were several 
factors showing immediate significance such as the patients 
pre-operative creatinine, the administration of adrenaline or 
noradrenaline post-operatively and the use of an intra-aortic 
balloon pump. It is generally acknowledged that the more 
unstable patients will sustain more myocardial injury and that 
the use of inotropes in themselves results in more myocardial 
enzyme release [9,10]. 
This first set of results display an interesting relationship, where it 
was shown that the bypass duration has a significant effect on the 
peak troponin I levels and hence on myocardial injury, however the 
relationships of peak troponin I levels with cardiac ischaemia times 
and cardioplegia volumes were not significant. This indicates that 
cardioplegia protects against myocardial ischaemic damage and 
therefore as single variables they will not have a direct effect on the 
peak troponin I levels. This, however, needs to be interpreted within 
the context of the time range in this study and with a maximum 
ischaemia time of 62 minutes, one can assume that this may not be 
the case in longer procedures. The conclusion thus far can be made 
that in coronary artery graft surgery of around one hour duration 
with standard myocardial protective techniques the ischaemia time 
is being well protected against and yet the time spent on bypass 
without myocardial protection causes significant myocardial injury.
The second set of results were obtained using a GLM to assess 
the impact of two variables and their interaction effect on peak 
troponin I level. Since CPB time was significant independently 
from other factors, the significance was not altered by any other 
factor besides the ischaemia time and the delivery of cardioplegia 
in multiple doses as opposed to one single dose. As shown in 
graph 3 the CPB and ischaemia time curves are positively and 
significantly related. This is in-keeping with current knowledge as 
longer procedures will include lengthening both times, however 
the previous observation shows they are not independently 
linked. The conclusion therefore is that while bypass time is itself 
significant on the peak troponin, the ischaemia time is not. The 
two-way ANOVA models with interaction, described in the results 
section, only identify bypass time as a significant predictor of 
peak troponin. The recommendation is that, within normal limits 
(62 minutes in this study), ischaemic injury is well suppressed with 
adequate cardioplegia, however prolongation of CPB is associated 
with more troponin release indicating an insult to the myocardium. 
These findings may suggest that CPB per se causes myocardial 
damage independently of cross clamp induced myocardial 
ischaemia. Also the inference might be made that less 
Graph 3. Scatter plot showing relationships between Ischaemia 
time, Bypass time and Log Peak Troponin
Table 1. P-values of each univariate analysis 
Predictor P Value Predictor P Value
Logistic Euroscore 0.062 pH 0.953
Age 0.056 Na 0.772
Sex 0.431 Cl 0.483
Weight 0.230 Ca 0.224
BSA 0.163 Gluc 0.229
DM 0.447 Creatinine 0.014
HT 0.964 Dopamine 0.944
Unstable Angina 0.565 Adrenaline 0.001
Vol 1 0.726 Noradrenaline 0.001
Ischaemia 1 0.889 Milrinone 0.958
Vol 2 0.389 IABP 0.017
Ischaemia 2 0.683 EDV 0.085
Vol 3 0.243 ESV 0.952
Ischaemia 3 0.416 SV 0.864
Vol 4 0.326 LMS 0.566
Ischaemia 4 0.135 Diffuse Disease 0.426
Total CP Vol 0.956 Statins 0.545
Ischaemia Time 0.097 Vastarel 0.107
Ejection fraction 0.090 VF during plegia and shock 0.615
Bypass time 0.033 VF after removing cross clamp 0.907
CP Potassium 0.408 Multidose CP 0.092
CP O2 0.636 Total CP vol above or below 750 0.932
Hct 0.070
P-values marked in yellow are less than the 0.05 level of significance, 
while p-values marked in green range from 0.05 to 0.1. Ischaemia 
1,2,3 and 4 refer to the time in-between doses of cardioplegia.
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myocardial damage occurs if the cardioplegia protection of the 
heart with an aortic cross clamp is increased with consequent 
reduction of beating heart CPB unprotected by cardioplegia. 
One such scenario is the performance of aorto-saphenous vein 
anastomoses (proximal anastomoses) with the aortic cross clamp 
in situ hence delaying myocardial activity during CPB. This may 
be the reason why the patients receiving multidose cardioplegia 
had some protection against a longer bypass time (graph 4). 
It is possible that the effect of cardioplegia continued into the 
proximal anastomosis and the delayed onset of myocardial 
activity allowed for better protection.
The concept of adequate cardioplegia mentioned earlier was 
also assessed using this data. The total amount of cardioplegia 
solution given and its administration in multiple doses rather 
than one single dose was linked to longer CPB and cardiac 
ischaemia times. The critical volume of cardioplegia below 
which there was a statistically significantly larger release of 
troponin was 750mls. Hence, a total of 750mls or more of 
cardioplegia given in multiple doses as required offer the best 
protection for moderate to good ejection fraction patients 
within  ischaemic times of up to 62 minutes and a CPB time of 
up to 116 minutes. As shown in graph 5 the ischaemia time will 
only raise the peak troponin if too little cardioplegia is given. 
Independently, ischaemia time and total cardioplegia volume 
did not show significant effect on peak troponin I levels but 
the combined effect attained significance. The statistical 
significance of this combination increases as the total volume 
of cardioplegia administered increases. The timing of these 
multiple doses did not have any significant effect on the peak 
troponin when identified as individual variables in table 1 
(ischaemia 1,2,3 and 4).
There are multiple reasons why the time spent on CPB causes 
greater myocardial cell damage. An important factor is the 
haemodynamic changes in coronary blood flow during the non-
pulsatile flow of CPB. The collapsed heart causes increased 
subendocardial vascular resistance and when  this is coupled 
with a narrow pulse pressure and a reduced mean arterial 
Graph 4. Relationship between log peak troponin, bypass time 
and CP doses
Graph 5. Relationship between log peak troponin, ischaemia 
time and CP volume
Table 5. Tests of Between-Subjects Effects  
(Dependent variable – Log PeakTroponin)
Source
Sum of 
Squares df
Mean 
Square F P-value
Intercept 4.068 1 4.068 20.888 0.000
IschaemiaTime 0.669 1 0.669 3.431 0.066
CatCPVol 0.342 1 0.342 1.757 0.187
CatCPVol * 
IschaemiaTime 0.451 1 0.451 2.316 0.130
Error 31.94 164 0.195
Graph 5 displays the relationship between log peak troponin, 
ischaemia time and a grouped version of CP volume.  It shows 
that log peak troponin increases with an increase in ischaemia 
time; however this increase is more conspicuous for patients 
taking less than 750 ml.  For patients given less than 750 ml CP 
dose, the log peak troponin is larger in a long ischeamia times and 
smaller in short ischeamia times, compared to patients given more 
than 750 ml CP dose. Tests of between-subject effects show that 
none of the effects are significant at the 0.05 level of significance, 
indicating that these relationships may be attributed to chance.
Table 4 Tests of Between-Subjects Effects  
(Dependent variable – Log PeakTroponin)
Source
Sum of 
Squares df
Mean 
Square F P-value
Intercept 1.070 1 1.070 5.751 0.018
ByPassTime 1.779 1 1.779 9.564 0.002
MultidoseCP 1.317 1 1.317 7.078 0.009
MultidoseCP * 
ByPassTime 1.303 1 1.303 7.003 0.009
Error 30.69 165 0.186
Graph 4 shows the relationship between log peak troponin, 
bypass time and a grouped version of the number of CP doses. 
Tests of between-subject effects show that both main effects 
and their interaction effects are significant since their p-values 
are less than the 0.05 level of significance. Graph 4 displays that 
log peak troponin increases with an increase in bypass time; 
however this increase is more conspicuous for patients taking 
one dose. For patients given one CP dose, the log peak troponin 
is larger in a long bypass durations and smaller in short bypass 
durations, compared to patients given multiple CP doses.
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pressure the result is poorer perfusion of the subendocardial 
layer [11]. The subendocardial layer is very vulnerable to 
ischaemia, partly due to its higher oxygen requirements [12]. 
Furthermore the relatively empty left ventricle reduces the 
direct contact of intraventricular oxygenated blood to the 
subendocardial layers [13]. Also, the generalised inflammatory 
response induced by CPB, causing platelet aggregation and 
endothelial activation may induce microscopic occlusions of 
tiny myocardial capillaries [14]. When considering that all the 
patients in this study suffer from ischaemic heart disease it is 
plausible that they have little reserve to tolerate any of the above 
changes and therefore suffer ischaemia during the CPB which 
may be of greater significance than the aortic cross-clamp time. 
Limitations
The best method available during this study to identify myocardial 
cell damage was a serum troponin level. This investigation is 
significantly altered by postoperative ischaemia and infarction. 
Therefore the intraoperative damage may not have been the 
cause of the raised troponin values in some patients. Every effort 
was made to exclude patients with any sign of post-operative 
ischaemic events that would alter their troponin level. However 
once a patient was recruited into the study no selection bias was 
permitted and even those with seemingly excessive troponin 
rises were included.
Another limitation is the absence of patients with poor ventricular 
function and the small number of patients with moderate ventricular 
function. This was not an intentional selection bias but was purely 
coincidental. In a small unit such as this one the majority of routine 
CABG cases have a good ejection fraction. This limits the study in 
that the conclusions can only be applied to patients with moderate 
to good ejection fractions and must not be applied to weaker hearts 
which may require more insense myocardial protection strategies.
Conclusion
In patients with moderate or good ventricular function, myocardial 
protection using 750 mls or more of cold blood cardioplegia 
is sufficient to prevent the ischaemic time from significantly 
affecting the post-operative peak troponin levels. The same can 
not be said for the bypass time which has a direct linear effect on 
post-operative troponin levels and therefore must be considered 
as a vulnerability in standard myocardial protection techniques. 
Graph 6. Relationship between log peak troponin, CP volume 
and CP doses
Graph 7. Relationship between log peak troponin, ischaemia 
time and CP doses
Table 7 Tests of Between-Subjects Effects (Dependent variable – 
Log PeakTroponin)
Source
Sum of 
Squares df
Mean 
Square F P-value
Intercept 3.388 1 3.388 17.170 0.000
IschaemiaTime 0.145 1 0.145 0.736 0.392
MultidoseCP 0.026 1 0.026 0.132 0.716
MultidoseCP * 
IschaemiaTime 0.007 1 0.007 0.033 0.855
Error 32.36 164 0.197
Graph 7 displays the relationship between log peak troponin, 
ischaemia time and a grouped version of the number of CP doses. 
It shows that log peak troponin increases with an increase in 
ischaemia time; however this increase is slightly more conspicuous 
for patients taking one CP dose.  Tests of between-subject effects 
show that none of the effects are significant at the 0.05 level, 
indicating that these relationships may be attributed to chance.
Table 6 Tests of Between-Subjects Effects (Dependent variable – 
Log PeakTroponin)
Source
Sum of 
Squares df
Mean 
Square F P-value
Intercept 4.645 1 4.645 23.613 0.000
TotalCPVol 0.012 1 0.012 0.061 0.805
MultidoseCP 0.207 1 0.207 1.051 0.307
MultidoseCP * 
TotalCPVol 0.079 1 0.079 0.399 0.528
Error 32.46 165 0.197
Graph 6 displays the relationship between log peak troponin, 
CP volume and a grouped version of the number of CP doses. It 
shows that log peak troponin increases marginally with an increase 
in total CP volume when one CP dose is provided; however, log 
peak troponin decreases marginally with an increase in total CP 
volume when multiple CP doses are provided. Tests of between-
subject effects show that none of the effects are significant at the 
0.05 level of significance, indicating that these relationships may be 
attributed to chance.
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The ischaemia time is shown to effect post-operative troponin 
when less than 750mls of cardioplegia is given. This confirms 
that adequate myocardial protection requires a total cardioplegia 
volume of 750 mls or more. The data also shows that this is 
ideally given in multiple doses as required but the specific timing 
of these doses or the number of separate cardioplegia injections 
were not significant.
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